CloneID: PolrecCHOIgM/GD3
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was developed by isolating heavy and light chain cDNAs from a hybridoma producing an anti-GD3 IgM antibody. These sequences were then codon-optimized and transfected into CHO cells to produce the recombinant PolrecCHOIgM/GD3 antibody.
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgM format, created for improved compatibility with existing reagents, assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Specificity Statement: This antibody is specific for human GD3, GM1, GD2, and GM3 gangliosides.
Application Notes (Clone): The original antibody (recombinant human IgM) was designed to bind the ganglioside GD3, which is overexpressed in malignant cells like melanomas. ELISA testing revealed strong binding specificity to GD3, GM1, GD2, and GM3 gangliosides, even at low concentrations. In cell-line assays, it selectively bound cancer cell lines (melanoma, lung, breast, and glioblastoma), without binding to normal cells such as huVEC and lung fibroblasts. Immunoimaging confirmed this selective binding, with fluorescence indicating strong interaction with malignant cells. In vitro complement activation tests showed that the antibody triggered cancer cell lysis when exposed to normal human serum, demonstrating its ability to activate the complement cascade. The antibody thus effectively discriminates between malignant and normal cells, confirming its diagnostic and therapeutic utility in cancer (US10590204B2).
English
Deutsch
